Original articleCollaborative Ocular Oncology Group Report Number 1: Prospective Validation of a Multi-Gene Prognostic Assay in Uveal Melanoma
Section snippets
Patient Data and Tumor Samples
This study was conducted with the approval of the institutional review board or ethics committee of each participating institution. Informed consent was obtained from each patient, and the study adhered to the tenets of the Declaration of Helsinki. All work using patient information was performed in compliance with the Health Insurance Portability and Accountability Act. Inclusion criteria for the study patients were (1) clinical diagnosis of uveal melanoma and (2) investigational informed
Baseline Information
The study design is outlined in Figure 1. The GEP prognostic assay was performed on 459 posterior uveal melanomas obtained prospectively from 12 participating institutions. A total of 224 patients were female, and 235 patients were male. The mean age was 61.7 years (median, 61.0 years). The mean tumor diameter was 12.8 mm (median, 12.7 mm), and mean tumor thickness was 6.3 mm (median, 5.5 mm). Ciliary body involvement was absent in 308 cases, present in 139 cases, and unknown in 12 cases. Tumor
Comparison of Gene Expression Profiling with Chromosome 3 Status
Because monosomy 3 has been widely used as a prognostic marker for uveal melanoma, we wanted to study more closely the relationship between GEP and chromosome 3 status. Chromosome 3 status was collected from the first 260 cases, of which the GEP/chromosome 3 status was class 1/disomy 3 in 119 (45.8%), class 2/monosomy 3 in 87 (33.5%), class 1/monosomy 3 in 38 (14.6%), and class 2/disomy 3 in 16 (6.2%) (Fig 3A). As expected, there was a significant association between class 1 and disomy 3, and
Discussion
In this prospective multicenter collaborative study, the prognostic accuracy of a 15-gene prognostic assay for uveal melanoma was assessed. A strong association was observed between GEP class 2 and other adverse prognostic factors, including increased patient age, ciliary body involvement, larger tumor diameter and thickness, epithelioid cell type, and monosomy 3. However, GEP class was more strongly associated with metastasis than these other factors. In multivariate analysis, no combination
Acknowledgments
The authors thank Dr. Steve Kymes for statistical consultation.
References (25)
- et al.
Uveal melanoma: trends in incidence, treatment, and survival
Ophthalmology
(2011) - et al.
Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment
Ophthalmology
(2000) - et al.
Effectiveness of treatments for metastatic uveal melanoma
Am J Ophthalmol
(2009) - et al.
Monosomy 3 and isochromosome 8q in a uveal melanoma
Cancer Genet Cytogenet
(1990) - et al.
Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens
J Mol Diagn
(2006) - et al.
An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma
J Mol Diagn
(2010) - et al.
Fluorescent in situ hybridization for monosomy 3 via 30-gauge fine-needle aspiration biopsy of choroidal melanoma in vivo
Ophthalmology
(2007) - et al.
Current management of uveal melanoma
Expert Rev Ophthalmol
(2007) - et al.
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death
Cancer Res
(2004) - et al.
Frequent mutation of BAP1 in metastasizing uveal melanomas
Science
(2010)
Nonrandom chromosomal abnormalities in primary uveal melanoma
J Natl Cancer Inst
Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8
Genes Chromosomes Cancer
Cited by (0)
Manuscript no. 2011-1353.
Financial Disclosure(s): The author(s) have made the following disclosure(s): Dr. Harbour and Washington University may receive royalties based on a license of related technology by the University to Castle Biosciences, Inc. This research was not funded by Castle Biosciences, Inc.
This work was supported by grants (to J.W.H.) from the National Cancer Institute (R01 CA125970), Barnes-Jewish Hospital Foundation, Kling Family Foundation, Tumori Foundation, Horncrest Foundation, and a Research to Prevent Blindness David F. Weeks Professorship, and by awards to the Department of Ophthalmology and Visual Sciences at Washington University from a Research to Prevent Blindness Inc unrestricted grant, and the National Institutes of Health Vision Core Grant P30 EY02687c.